Director/PDMR Shareholding

8 September 2015

Source BioScience plc

(the 'Company')

Exercise of Share Options and Directors' Dealings

Source BioScience plc (LSE: SBS) announces that on 7 September it issued and allotted 3,878,854 new ordinary shares of 2 pence each in the Company (the 'New Ordinary Shares'), representing 1.11% of its enlarged issued share capital, following the net exercise of share options by certain Directors and other option holders under the Source BioScience plc Share Option Schemes at an effective net exercise price of nil.

As a result of the net exercise of share options:

· Mr Laurence Turnbull, Chairman was allotted 2,041,667 New Ordinary Shares in full settlement of his 2007 share option awards which totalled 3,750,000 share options

· Dr Nick Ash, Chief Executive Officer was allotted 1,454,243 New Ordinary Shares in full settlement of his 2006 and 2007 share option awards which totalled 2,500,000 share options

· Dr Nick Leaves, Chief Operating Officer was allotted 265,152 New Ordinary Shares in full settlement of his 2007 share option awards which totalled 500,000 shares

The Company also announces that it was notified on 7 September 2015 that, following the exercise of share options, Mr Turnbull sold 2,041,667 Ordinary Shares; Dr Ash sold 1,454,243 Ordinary Shares and Dr Leaves sold 265,152 Ordinary Shares, all at 16.50p per Ordinary Share on 7 September 2015. Following the exercise of share options and the sale of Ordinary Shares, the number of Ordinary Shares held by each Director remains unchanged.

Application has been made for the New Ordinary Shares to be admitted to the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange. It is expected that admission of the New Ordinary Shares will occur on or around 8 September 2015

Following the issue and allotment, the Company's issued share capital will comprise 349,100,255 ordinary shares of 2 pence each, which figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, Source BioScience plc under the FSA's Disclosure and Transparency Rules. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares and no Ordinary Shares are held in treasury.

This notification is provided in accordance with DTR3.1.4R(1).

--- ENDS ---

For further information, please contact:

Source BioScience plc

Dr Nick Ash, CEO and Company Secretary

Tel: +44 (0)115 973 9010

Email: [email protected]

www.sourcebioscience.com

N+1 Singer (Financial Advisor, Sponsor and Broker)

Aubrey Powell/James White

Tel: +44 (0)207 496 3000

www.n1singer.com

About Source BioScience

Source BioScience plc (LSE: SBS) is a trusted provider of state of the art laboratory services and products to the healthcare and clinical, life and applied sciences and biopharma industries. It is an international business operating ten state of the art facilities in five countries and with customers in over 90 countries worldwide. The Group offers a complementary portfolio of laboratory services and products that share common technologies, laboratory processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These services and products are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange.